Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110)
-
Published:2024-05
Issue:5
Volume:9
Page:103374
-
ISSN:2059-7029
-
Container-title:ESMO Open
-
language:en
-
Short-container-title:ESMO Open
Author:
Boukovala M.,
Modest D.P.,
Ricard I.,
Fischer von Weikersthal L.,
Decker T.,
Vehling-Kaiser U.,
Uhlig J.,
Schenk M.,
Freiberg-Richter J.,
Peuser B.,
Denzlinger C.,
Peveling Genannt Reddemann C.,
Graeven U.,
Schuch G.ORCID,
Schwaner I.ORCID,
Heinrich K.,
Neumann J.,
Jung A.,
Held S.,
Stintzing S.ORCID,
Heinemann V.,
Michl M.ORCID
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献